{"gene":"ALDH16A1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2009,"finding":"ALDH16A1 physically interacts with the SPG21 protein ACP33/maspardin. This interaction was identified by immunoprecipitation of maspardin followed by mass spectrometry, confirmed by co-immunoprecipitation of overexpressed proteins and fusion protein pull-down experiments, and the two proteins colocalize in cells. Maspardin localizes to cytoplasm and trans-Golgi network/late endosomal compartments.","method":"Co-immunoprecipitation with mass spectrometry identification, fusion protein pull-down, cellular colocalization","journal":"Neurogenetics","confidence":"Medium","confidence_rationale":"Tier 2-3 — reciprocal pull-down and colocalization, single lab","pmids":["19184135"],"is_preprint":false},{"year":2013,"finding":"Human ALDH16A1 is predicted to be a non-catalytic pseudoenzyme due to the absence of the essential catalytic cysteine residue (Cys-302) that is present in bacterial, frog, and lower-animal ALDH16 orthologs. Molecular modeling predicts that both the long and short splice forms of ALDH16A1 lack aldehyde oxidation activity but can interact with HPRT1 (hypoxanthine-guanine phosphoribosyltransferase), a key enzyme in uric acid metabolism, and that the gout-associated missense variant ALDH16A1*2 impairs this predicted interaction.","method":"Molecular modeling, computational structural analysis, sequence comparison across species","journal":"Chemico-biological interactions","confidence":"Low","confidence_rationale":"Tier 4 — computational prediction only, no in vitro validation of interaction or loss of catalytic activity","pmids":["23348497"],"is_preprint":false},{"year":2017,"finding":"ALDH16A1 is expressed in proximal and distal convoluted tubule cells in the kidney cortex and in zone 3 hepatocytes. In Aldh16a1 knockout mice, RNA-seq revealed upregulation of cellular lipid metabolic processes and dysregulation of urate transporters in the kidney proximal tubule: Abcc4 and Slc16a9 were up-regulated while Slc17a3 was down-regulated. Plasma metabolomics showed an altered lipid profile in KO mice, demonstrating a functional role of ALDH16A1 in renal uric acid/urate homeostasis.","method":"Gene targeting (knockout mouse), RNA-seq, gene ontology enrichment analysis, plasma metabolomics, immunohistochemistry for localization","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with defined transcriptomic and metabolomic phenotypes, single lab with multiple orthogonal methods","pmids":["28254523"],"is_preprint":false},{"year":2018,"finding":"Crystal structures of bacterial ALDH16 (Loktanella sp.) were determined at high resolution, revealing a three-domain fold (NAD+-binding, catalytic, and C-terminal Rossmann-fold domain unique to ALDH16). The C-terminal domain mimics the quaternary dimer interface of classic ALDHs ('trans-hierarchical structural similarity'). ALDH16 forms a unique dimer in solution that mimics the classic ALDH dimer-of-dimer tetramer. Loktanella ALDH16 exhibits NAD+-binding, aldehyde oxidation activity, and esterase activity. In contrast, recombinant human ALDH16A1 lacks measurable aldehyde oxidation activity, confirming it is a pseudoenzyme, consistent with absence of the catalytic Cys. Small-angle X-ray scattering shows human ALDH16A1 adopts the same dimeric structure and fold as Loktanella ALDH16.","method":"Recombinant protein expression, X-ray crystallography (four high-resolution structures), in vitro enzymatic assays, small-angle X-ray scattering (SAXS)","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure combined with in vitro biochemical characterization and SAXS validation of human protein","pmids":["30529746"],"is_preprint":false},{"year":2019,"finding":"The Xenopus tropicalis homolog of ALDH16A1, ALDH16B1, was recombinantly expressed in Sf9 cells and crystallized, with a dataset collected at 2.5 Å (space group P 212121). Unlike mammalian ALDH16A1, frog ALDH16B1 was predicted to be catalytically active (possessing the critical Cys residue), providing comparative structural insight into the evolutionary loss of catalytic activity in the mammalian protein.","method":"Recombinant expression in Sf9 cells, affinity and size-exclusion chromatography purification, vapor diffusion crystallization, X-ray data collection","journal":"Chemico-biological interactions","confidence":"Low","confidence_rationale":"Tier 3 — crystallization reported but structure determination not yet complete at time of publication; preliminary structural data only","pmids":["30894314"],"is_preprint":false},{"year":2025,"finding":"ALDH16A1 expression is transcriptionally promoted by SMARCA4 via chromatin accessibility. Despite lacking ALDH enzymatic activity, ALDH16A1 binds directly to thioredoxin (TXN), facilitating TXN translocation to the lysosome and its subsequent degradation. Additionally, ALDH16A1 directly inhibits TXN's oxidoreductase function by occluding TXN's active site. This dual regulation (promoting TXN lysosomal degradation and blocking TXN enzymatic activity) sensitizes SMARCA4-deficient NSCLC cells to ferroptosis. Restoring ALDH16A1 or inhibiting TXN enhances chemo/immunotherapy efficacy in a ferroptosis-dependent manner.","method":"ATAC-seq (chromatin accessibility), co-immunoprecipitation, cellular TXN localization/degradation assays, in vitro TXN activity assays, ferroptosis functional assays, SMARCA4 KO/rescue experiments, in vivo tumor models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including biochemical binding, enzymatic inhibition assay, and in vivo functional validation in a single study","pmids":["40897711"],"is_preprint":false}],"current_model":"ALDH16A1 is a pseudoenzyme (confirmed by crystal structure and in vitro assays) that lacks aldehyde oxidation activity due to absence of the catalytic cysteine; it forms a unique dimer, is expressed in kidney tubule cells and hepatocytes, interacts with maspardin/ACP33 and thioredoxin (TXN), and mechanistically promotes ferroptosis by binding TXN to facilitate its lysosomal degradation and by occluding TXN's active site, placing ALDH16A1 within a SMARCA4-ALDH16A1-TXN regulatory axis that governs ferroptosis susceptibility."},"narrative":{"teleology":[{"year":2009,"claim":"Identifying ALDH16A1's first physical interaction partner established that this uncharacterized ALDH family member participates in protein–protein interactions, specifically with the spastic paraplegia gene product maspardin/ACP33.","evidence":"Co-immunoprecipitation with mass spectrometry, reciprocal pull-down, and colocalization of overexpressed proteins in mammalian cells","pmids":["19184135"],"confidence":"Medium","gaps":["Functional consequence of the ALDH16A1–maspardin interaction is unknown","Endogenous interaction not validated","No structural detail on the binding interface"]},{"year":2013,"claim":"Computational analysis predicted that mammalian ALDH16A1 is a non-catalytic pseudoenzyme (lacking the essential Cys-302) and proposed an interaction with the purine salvage enzyme HPRT1 that could link ALDH16A1 to uric acid metabolism.","evidence":"Molecular modeling, sequence alignment across species, and structural prediction of HPRT1 binding","pmids":["23348497"],"confidence":"Low","gaps":["HPRT1 interaction was computationally predicted only and has not been experimentally validated","Pseudoenzyme status was inferred from sequence alone without biochemical confirmation","Gout-associated variant effect on interaction remains unconfirmed experimentally"]},{"year":2017,"claim":"Generation of Aldh16a1 knockout mice revealed that loss of ALDH16A1 dysregulates urate transporters and lipid metabolism in the kidney, establishing an in vivo non-enzymatic regulatory function and defining its tissue expression pattern.","evidence":"Gene-targeted knockout mouse with RNA-seq, plasma metabolomics, and immunohistochemistry","pmids":["28254523"],"confidence":"Medium","gaps":["Molecular mechanism by which ALDH16A1 influences urate transporter expression is unknown","Direct binding partners mediating the renal phenotype were not identified","Single-lab study without independent replication"]},{"year":2018,"claim":"Crystal structures of bacterial ALDH16 and SAXS analysis of human ALDH16A1 definitively confirmed the pseudoenzyme status and revealed a unique three-domain fold with a C-terminal Rossmann-like domain that creates a novel dimeric architecture mimicking the classic ALDH tetramer.","evidence":"High-resolution X-ray crystallography of Loktanella ALDH16 (four structures), in vitro aldehyde oxidation and esterase assays, SAXS on recombinant human ALDH16A1","pmids":["30529746"],"confidence":"High","gaps":["No high-resolution crystal structure of human ALDH16A1 itself","Whether the NAD+-binding site in human ALDH16A1 retains any ligand-binding function is untested","Structural basis for any protein–protein interaction is unresolved"]},{"year":2025,"claim":"Discovery that ALDH16A1 directly binds TXN, occludes its active site, and promotes its lysosomal degradation provided the first complete molecular mechanism for the pseudoenzyme, placing it in a SMARCA4–ALDH16A1–TXN axis that governs ferroptosis susceptibility in cancer cells.","evidence":"ATAC-seq, co-immunoprecipitation, TXN enzymatic activity assays, lysosomal translocation/degradation assays, SMARCA4 KO/rescue, and in vivo tumor models in NSCLC","pmids":["40897711"],"confidence":"High","gaps":["Structural basis of ALDH16A1–TXN binding and active-site occlusion has not been resolved at atomic resolution","Whether the SMARCA4–ALDH16A1–TXN axis operates in non-cancerous tissues (e.g., kidney) is unknown","Relationship between the TXN-regulatory function and the previously observed maspardin interaction is unexplored"]},{"year":null,"claim":"Key unresolved questions include the atomic-resolution structure of human ALDH16A1 in complex with TXN, whether the predicted HPRT1 interaction exists and connects to the renal urate phenotype, and how ALDH16A1's pseudoenzyme scaffold integrates maspardin binding with TXN regulation.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of human ALDH16A1 alone or in complex with any partner","HPRT1 interaction never experimentally validated","Functional integration of maspardin and TXN interactions is completely unexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,2]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5]}],"complexes":[],"partners":["TXN","SPG21","SMARCA4"],"other_free_text":[]},"mechanistic_narrative":"ALDH16A1 is a pseudoenzyme member of the aldehyde dehydrogenase superfamily that has lost catalytic aldehyde oxidation activity due to the absence of the conserved catalytic cysteine, as confirmed by crystal structure determination, SAXS, and in vitro enzymatic assays [PMID:30529746]. It retains the three-domain ALDH fold and forms a unique homodimer that mimics the classic ALDH dimer-of-dimers architecture [PMID:30529746]. ALDH16A1 is expressed in kidney proximal and distal tubule cells and zone 3 hepatocytes; knockout mice exhibit dysregulated urate transporter expression and altered lipid metabolism, indicating a non-enzymatic regulatory role in renal homeostasis [PMID:28254523]. ALDH16A1 directly binds thioredoxin (TXN), occluding its active site and promoting its lysosomal degradation, thereby sensitizing cells to ferroptosis within a SMARCA4–ALDH16A1–TXN regulatory axis [PMID:40897711]."},"prefetch_data":{"uniprot":{"accession":"Q8IZ83","full_name":"Aldehyde dehydrogenase family 16 member A1","aliases":[],"length_aa":802,"mass_kda":85.1,"function":"","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q8IZ83/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ALDH16A1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000161618","cell_line_id":"CID000980","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"vesicles","grade":3}],"interactors":[{"gene":"DERA","stoichiometry":10.0},{"gene":"TRIAP1","stoichiometry":0.2},{"gene":"KIAA0430","stoichiometry":0.2},{"gene":"DCTN2","stoichiometry":0.2},{"gene":"PRR14L","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000980","total_profiled":1310},"omim":[{"mim_id":"614747","title":"URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 6; UAQTL6","url":"https://www.omim.org/entry/614747"},{"mim_id":"614746","title":"URIC ACID CONCENTRATION, SERUM, QUANTITATIVE TRAIT LOCUS 5; UAQTL5","url":"https://www.omim.org/entry/614746"},{"mim_id":"613358","title":"ALDEHYDE DEHYDROGENASE 16 FAMILY, MEMBER A1; ALDH16A1","url":"https://www.omim.org/entry/613358"},{"mim_id":"608181","title":"ACIDIC CLUSTER PROTEIN, 33-KD; ACP33","url":"https://www.omim.org/entry/608181"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ALDH16A1"},"hgnc":{"alias_symbol":["MGC10204"],"prev_symbol":[]},"alphafold":{"accession":"Q8IZ83","domains":[{"cath_id":"3.40.605.10","chopping":"27-274_484-488","consensus_level":"high","plddt":94.2785,"start":27,"end":488},{"cath_id":"3.40.309.10","chopping":"278-458","consensus_level":"high","plddt":92.7153,"start":278,"end":458},{"cath_id":"3.40.605.10","chopping":"531-790","consensus_level":"high","plddt":92.9315,"start":531,"end":790}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IZ83","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IZ83-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IZ83-F1-predicted_aligned_error_v6.png","plddt_mean":91.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ALDH16A1","jax_strain_url":"https://www.jax.org/strain/search?query=ALDH16A1"},"sequence":{"accession":"Q8IZ83","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8IZ83.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8IZ83/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IZ83"}},"corpus_meta":[{"pmid":"21983786","id":"PMC_21983786","title":"Identification of low-frequency variants associated with gout and serum uric acid levels.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21983786","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19184135","id":"PMC_19184135","title":"Interaction of the SPG21 protein ACP33/maspardin with the aldehyde dehydrogenase ALDH16A1.","date":"2009","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19184135","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23348497","id":"PMC_23348497","title":"ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1.","date":"2013","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/23348497","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20927131","id":"PMC_20927131","title":"A DEAB-sensitive aldehyde dehydrogenase regulates hematopoietic stem and progenitor cells development during primitive hematopoiesis in zebrafish embryos.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/20927131","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35116021","id":"PMC_35116021","title":"The ALDH Family Contributes to Immunocyte Infiltration, Proliferation and Epithelial-Mesenchymal Transformation in Glioma.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35116021","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28254523","id":"PMC_28254523","title":"Transcriptomic analysis and plasma metabolomics in Aldh16a1-null mice reveals a potential role of ALDH16A1 in renal function.","date":"2017","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/28254523","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30529746","id":"PMC_30529746","title":"Crystal Structure of Aldehyde Dehydrogenase 16 Reveals Trans-Hierarchical Structural Similarity and a New Dimer.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30529746","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34732286","id":"PMC_34732286","title":"The genetic basis of urate control and gout: Insights into molecular pathogenesis from follow-up study of genome-wide association study loci.","date":"2021","source":"Best practice & research. Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/34732286","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30894314","id":"PMC_30894314","title":"Expression, purification and crystallization of the novel Xenopus tropicalis ALDH16B1, a homologue of human ALDH16A1.","date":"2019","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/30894314","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40897711","id":"PMC_40897711","title":"Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40897711","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38644525","id":"PMC_38644525","title":"Single-nucleus transcriptomics and chromatin accessibility analysis of musk gland development in Chinese forest musk deer (Moschus berezovskii).","date":"2024","source":"Integrative zoology","url":"https://pubmed.ncbi.nlm.nih.gov/38644525","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40898360","id":"PMC_40898360","title":"Identification and validation of a tear fluid-derived protein biomarker signature in patients with amyotrophic lateral sclerosis.","date":"2025","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/40898360","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40537683","id":"PMC_40537683","title":"Druggable Targets for Postpartum Depression: A Mendelian Randomization and Colocalization Study.","date":"2025","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/40537683","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41328062","id":"PMC_41328062","title":"Syndrome Differentiation and Treatment of Psoriasis by Traditional Chinese Medicines: An Integrating Study of Multi-Omics Analysis and Experimental Validation.","date":"2025","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/41328062","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16751776","id":"PMC_16751776","title":"A germline-specific class of small RNAs binds mammalian Piwi proteins.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16751776","citation_count":1362,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22863883","id":"PMC_22863883","title":"A high-throughput approach for measuring temporal changes in the interactome.","date":"2012","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/22863883","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32344865","id":"PMC_32344865","title":"Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32344865","citation_count":146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23376485","id":"PMC_23376485","title":"Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.","date":"2013","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23376485","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28986522","id":"PMC_28986522","title":"Mammalian APE1 controls miRNA processing and its interactome is linked to cancer RNA metabolism.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28986522","citation_count":99,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32814769","id":"PMC_32814769","title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32814769","citation_count":90,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32707033","id":"PMC_32707033","title":"Kinase Interaction Network Expands Functional and Disease Roles of Human Kinases.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32707033","citation_count":88,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33417871","id":"PMC_33417871","title":"UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex.","date":"2021","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/33417871","citation_count":78,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31452512","id":"PMC_31452512","title":"Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31452512","citation_count":77,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35256949","id":"PMC_35256949","title":"Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35256949","citation_count":66,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32687490","id":"PMC_32687490","title":"Proteome-wide identification of HSP70/HSC70 chaperone clients in human cells.","date":"2020","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/32687490","citation_count":65,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35831314","id":"PMC_35831314","title":"Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35831314","citation_count":65,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25921289","id":"PMC_25921289","title":"Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation.","date":"2015","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/25921289","citation_count":61,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8619474","id":"PMC_8619474","title":"A \"double adaptor\" method for improved shotgun library construction.","date":"1996","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8619474","citation_count":53,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"37054706","id":"PMC_37054706","title":"ATG5 provides host protection acting as a switch in the atg8ylation cascade between autophagy and secretion.","date":"2023","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/37054706","citation_count":46,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31536960","id":"PMC_31536960","title":"Rewiring of the Human Mitochondrial Interactome during Neuronal Reprogramming Reveals Regulators of the Respirasome and Neurogenesis.","date":"2019","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/31536960","citation_count":45,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9110174","id":"PMC_9110174","title":"Large-scale concatenation cDNA sequencing.","date":"1997","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/9110174","citation_count":45,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30631154","id":"PMC_30631154","title":"LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition.","date":"2019","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30631154","citation_count":44,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8372,"output_tokens":1713,"usd":0.025406},"stage2":{"model":"claude-opus-4-6","input_tokens":4966,"output_tokens":1804,"usd":0.104895},"total_usd":0.283744,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":20251,"output_tokens":1948,"usd":0.044986},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":5441,"output_tokens":1804,"usd":0.108457}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"ALDH16A1 interacts physically with the SPG21 protein ACP33/maspardin, as identified by immunoprecipitation of maspardin followed by mass spectrometry, confirmed by co-immunoprecipitation of overexpressed proteins and fusion-protein pulldown experiments; the two proteins colocalize in cells, likely at trans-Golgi network/late endosomal compartments.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, fusion-protein pulldown, co-localization imaging\",\n      \"journal\": \"Neurogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus pulldown in single lab, moderate evidence\",\n      \"pmids\": [\"19184135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Human ALDH16A1 lacks catalytic activity because the essential catalytic cysteine (Cys-302) present in bacterial, frog, and lower-animal ALDH16 orthologs is absent from mammalian and fish orthologs. Molecular modeling predicts that human ALDH16A1 (both long and short splice forms) can interact with HPRT1, a key enzyme in uric acid metabolism, and that the gout-associated missense variant ALDH16A1*2 disrupts this predicted interaction.\",\n      \"method\": \"Bioinformatic sequence analysis, molecular modeling/docking\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no experimental binding or activity assay performed for human protein\",\n      \"pmids\": [\"23348497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In Aldh16a1 knockout mice, ALDH16A1 protein is expressed in proximal and distal convoluted tubule cells of the kidney cortex and in zone 3 hepatocytes. Loss of ALDH16A1 alters expression of urate transporters (Abcc4, Slc16a9 up-regulated; Slc17a3 down-regulated) and up-regulates lipid metabolic processes, indicating a functional role in renal uric acid homeostasis.\",\n      \"method\": \"Gene knockout mouse model, RNA-seq, immunohistochemistry/fractionation for localization, plasma metabolomics\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined transcriptomic and metabolomic phenotype, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"28254523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structures of bacterial (Loktanella sp.) ALDH16 were solved at high resolution, demonstrating that ALDH16 adopts a three-domain fold (NAD+-binding, catalytic, and unique C-terminal domain with Rossmann fold and β-flap). Loktanella ALDH16 is a bona fide enzyme with NAD+-binding, aldehyde oxidation, and esterase activity. Human ALDH16A1 lacks measurable aldehyde oxidation activity, confirming it is a pseudoenzyme consistent with absence of catalytic Cys. Small-angle X-ray scattering shows human ALDH16A1 adopts the same dimeric structure and fold as Loktanella ALDH16, forming a unique dimer that mimics the classic ALDH tetramer arrangement.\",\n      \"method\": \"X-ray crystallography (4 structures), in vitro enzyme assay (NAD+-binding, aldehyde oxidation, esterase), small-angle X-ray scattering (SAXS)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus in vitro biochemical assay; human pseudoenzyme status confirmed by direct activity measurement and SAXS\",\n      \"pmids\": [\"30529746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Xenopus tropicalis ALDH16B1 (the catalytically-active frog homolog of human ALDH16A1, possessing the conserved Cys active-site residue) was recombinantly expressed in Sf9 cells, purified, crystallized, and diffraction data collected to 2.5 Å, representing initial structural characterization of the catalytically-competent ALDH16 family member.\",\n      \"method\": \"Recombinant protein expression (Sf9 insect cells), affinity and size exclusion chromatography, X-ray crystallography (data collection)\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — partial structural work (data collected but structure not yet determined), single lab\",\n      \"pmids\": [\"30894314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ALDH16A1 (whose expression is promoted by SMARCA4-dependent chromatin accessibility) binds to thioredoxin (TXN), facilitates TXN translocation to the lysosome and its subsequent degradation, and directly inhibits TXN oxidoreductase activity by occluding its active site. This dual regulation of TXN stability and function sensitizes SMARCA4-deficient NSCLC cells to ferroptosis.\",\n      \"method\": \"Co-immunoprecipitation/binding assays, lysosomal fractionation, TXN activity assay, SMARCA4 KO/knockdown, ALDH16A1 overexpression/knockdown with ferroptosis readouts\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (binding assay, fractionation, enzymatic inhibition assay, genetic manipulation with defined phenotype) in single study\",\n      \"pmids\": [\"40897711\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Human ALDH16A1 is a non-catalytic pseudoenzyme (lacking the essential active-site Cys) that adopts a unique dimeric ALDH fold with an extra C-terminal domain; it functions through protein–protein interactions—binding maspardin/ACP33, and binding thioredoxin (TXN) to both redirect TXN to lysosomal degradation and occlude its active site—thereby regulating ferroptosis susceptibility, and plays a role in renal uric acid homeostasis likely through regulation of urate transporter expression.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"ALDH16A1 physically interacts with the SPG21 protein ACP33/maspardin. This interaction was identified by immunoprecipitation of maspardin followed by mass spectrometry, confirmed by co-immunoprecipitation of overexpressed proteins and fusion protein pull-down experiments, and the two proteins colocalize in cells. Maspardin localizes to cytoplasm and trans-Golgi network/late endosomal compartments.\",\n      \"method\": \"Co-immunoprecipitation with mass spectrometry identification, fusion protein pull-down, cellular colocalization\",\n      \"journal\": \"Neurogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal pull-down and colocalization, single lab\",\n      \"pmids\": [\"19184135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Human ALDH16A1 is predicted to be a non-catalytic pseudoenzyme due to the absence of the essential catalytic cysteine residue (Cys-302) that is present in bacterial, frog, and lower-animal ALDH16 orthologs. Molecular modeling predicts that both the long and short splice forms of ALDH16A1 lack aldehyde oxidation activity but can interact with HPRT1 (hypoxanthine-guanine phosphoribosyltransferase), a key enzyme in uric acid metabolism, and that the gout-associated missense variant ALDH16A1*2 impairs this predicted interaction.\",\n      \"method\": \"Molecular modeling, computational structural analysis, sequence comparison across species\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no in vitro validation of interaction or loss of catalytic activity\",\n      \"pmids\": [\"23348497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ALDH16A1 is expressed in proximal and distal convoluted tubule cells in the kidney cortex and in zone 3 hepatocytes. In Aldh16a1 knockout mice, RNA-seq revealed upregulation of cellular lipid metabolic processes and dysregulation of urate transporters in the kidney proximal tubule: Abcc4 and Slc16a9 were up-regulated while Slc17a3 was down-regulated. Plasma metabolomics showed an altered lipid profile in KO mice, demonstrating a functional role of ALDH16A1 in renal uric acid/urate homeostasis.\",\n      \"method\": \"Gene targeting (knockout mouse), RNA-seq, gene ontology enrichment analysis, plasma metabolomics, immunohistochemistry for localization\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined transcriptomic and metabolomic phenotypes, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28254523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structures of bacterial ALDH16 (Loktanella sp.) were determined at high resolution, revealing a three-domain fold (NAD+-binding, catalytic, and C-terminal Rossmann-fold domain unique to ALDH16). The C-terminal domain mimics the quaternary dimer interface of classic ALDHs ('trans-hierarchical structural similarity'). ALDH16 forms a unique dimer in solution that mimics the classic ALDH dimer-of-dimer tetramer. Loktanella ALDH16 exhibits NAD+-binding, aldehyde oxidation activity, and esterase activity. In contrast, recombinant human ALDH16A1 lacks measurable aldehyde oxidation activity, confirming it is a pseudoenzyme, consistent with absence of the catalytic Cys. Small-angle X-ray scattering shows human ALDH16A1 adopts the same dimeric structure and fold as Loktanella ALDH16.\",\n      \"method\": \"Recombinant protein expression, X-ray crystallography (four high-resolution structures), in vitro enzymatic assays, small-angle X-ray scattering (SAXS)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure combined with in vitro biochemical characterization and SAXS validation of human protein\",\n      \"pmids\": [\"30529746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The Xenopus tropicalis homolog of ALDH16A1, ALDH16B1, was recombinantly expressed in Sf9 cells and crystallized, with a dataset collected at 2.5 Å (space group P 212121). Unlike mammalian ALDH16A1, frog ALDH16B1 was predicted to be catalytically active (possessing the critical Cys residue), providing comparative structural insight into the evolutionary loss of catalytic activity in the mammalian protein.\",\n      \"method\": \"Recombinant expression in Sf9 cells, affinity and size-exclusion chromatography purification, vapor diffusion crystallization, X-ray data collection\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — crystallization reported but structure determination not yet complete at time of publication; preliminary structural data only\",\n      \"pmids\": [\"30894314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ALDH16A1 expression is transcriptionally promoted by SMARCA4 via chromatin accessibility. Despite lacking ALDH enzymatic activity, ALDH16A1 binds directly to thioredoxin (TXN), facilitating TXN translocation to the lysosome and its subsequent degradation. Additionally, ALDH16A1 directly inhibits TXN's oxidoreductase function by occluding TXN's active site. This dual regulation (promoting TXN lysosomal degradation and blocking TXN enzymatic activity) sensitizes SMARCA4-deficient NSCLC cells to ferroptosis. Restoring ALDH16A1 or inhibiting TXN enhances chemo/immunotherapy efficacy in a ferroptosis-dependent manner.\",\n      \"method\": \"ATAC-seq (chromatin accessibility), co-immunoprecipitation, cellular TXN localization/degradation assays, in vitro TXN activity assays, ferroptosis functional assays, SMARCA4 KO/rescue experiments, in vivo tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including biochemical binding, enzymatic inhibition assay, and in vivo functional validation in a single study\",\n      \"pmids\": [\"40897711\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ALDH16A1 is a pseudoenzyme (confirmed by crystal structure and in vitro assays) that lacks aldehyde oxidation activity due to absence of the catalytic cysteine; it forms a unique dimer, is expressed in kidney tubule cells and hepatocytes, interacts with maspardin/ACP33 and thioredoxin (TXN), and mechanistically promotes ferroptosis by binding TXN to facilitate its lysosomal degradation and by occluding TXN's active site, placing ALDH16A1 within a SMARCA4-ALDH16A1-TXN regulatory axis that governs ferroptosis susceptibility.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ALDH16A1 is a non-catalytic pseudoenzyme of the aldehyde dehydrogenase superfamily that functions through protein–protein interactions to regulate thioredoxin homeostasis and ferroptosis susceptibility. Human ALDH16A1 lacks the conserved catalytic cysteine required for aldehyde oxidation and possesses no measurable dehydrogenase activity, yet adopts a dimeric three-domain ALDH fold with a unique C-terminal Rossmann-fold domain [PMID:30529746]. ALDH16A1 binds thioredoxin (TXN), occludes its active site to inhibit oxidoreductase activity, and redirects TXN to lysosomal degradation, thereby sensitizing cells to ferroptosis when ALDH16A1 is de-repressed in SMARCA4-deficient contexts [PMID:40897711]. In the kidney, ALDH16A1 is expressed in proximal and distal convoluted tubule cells, where its loss alters urate transporter expression, implicating it in renal uric acid homeostasis [PMID:28254523].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of maspardin/ACP33 as a physical partner established that ALDH16A1 participates in protein–protein interactions, potentially at trans-Golgi/late endosomal compartments, rather than functioning solely as a metabolic enzyme.\",\n      \"evidence\": \"Co-immunoprecipitation, mass spectrometry, pulldown, and colocalization in overexpressing cells\",\n      \"pmids\": [\"19184135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequence of ALDH16A1–maspardin interaction not determined\",\n        \"Endogenous interaction not validated at endogenous expression levels\",\n        \"No disease-relevant phenotypic assay linked to the interaction\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Bioinformatic analysis revealed that mammalian ALDH16A1 lacks the catalytic cysteine conserved in lower organisms, raising the hypothesis that the human protein is a pseudoenzyme that acts through non-catalytic mechanisms.\",\n      \"evidence\": \"Sequence alignment and molecular modeling/docking (computational only)\",\n      \"pmids\": [\"23348497\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No experimental validation of pseudoenzyme status or HPRT1 binding was performed\",\n        \"Predicted HPRT1 interaction has not been confirmed biochemically\",\n        \"Functional relevance of gout-associated ALDH16A1*2 variant remains untested\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Knockout mouse studies demonstrated that ALDH16A1 has an in vivo role in renal uric acid homeostasis by regulating urate transporter gene expression, establishing a physiological function beyond any enzymatic activity.\",\n      \"evidence\": \"Aldh16a1 knockout mice with RNA-seq, immunohistochemistry, and plasma metabolomics\",\n      \"pmids\": [\"28254523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which ALDH16A1 regulates transporter gene expression is unknown\",\n        \"Whether the phenotype reflects direct protein interactions or indirect signaling is unresolved\",\n        \"Human relevance of the mouse phenotype not established\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Crystal structures of bacterial ALDH16 and SAXS analysis of human ALDH16A1 confirmed the pseudoenzyme status of the human protein and revealed a unique dimeric architecture that mimics the classic ALDH tetramer, providing the structural basis for its non-catalytic protein-interaction functions.\",\n      \"evidence\": \"X-ray crystallography of Loktanella ALDH16 (4 structures), in vitro enzyme assays, SAXS of human ALDH16A1\",\n      \"pmids\": [\"30529746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"High-resolution crystal structure of human ALDH16A1 itself not yet solved\",\n        \"Structural determinants of partner binding (maspardin, TXN) not mapped\",\n        \"Role of the unique C-terminal domain in protein–protein interactions not defined\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that ALDH16A1 binds TXN, occludes its active site, and directs it for lysosomal degradation unified the pseudoenzyme's molecular mechanism with a defined cellular outcome—regulation of ferroptosis sensitivity—and linked its expression to SMARCA4-dependent chromatin remodeling.\",\n      \"evidence\": \"Co-immunoprecipitation, lysosomal fractionation, TXN activity assay, SMARCA4 KO/knockdown, ALDH16A1 overexpression/knockdown with ferroptosis readouts in NSCLC cells\",\n      \"pmids\": [\"40897711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the ALDH16A1–TXN interface not resolved at atomic level\",\n        \"Whether TXN regulation accounts for the renal urate transporter phenotype is unknown\",\n        \"Relevance to non-NSCLC tissues and physiological (non-cancer) ferroptosis not established\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the structural basis of ALDH16A1–TXN and ALDH16A1–maspardin interactions, the mechanism linking ALDH16A1 to urate transporter regulation, the physiological relevance of the gout-associated ALDH16A1*2 variant, and whether ALDH16A1's pseudoenzyme scaffold has additional binding partners beyond TXN and maspardin.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of human ALDH16A1 with any binding partner\",\n        \"Molecular mechanism connecting ALDH16A1 to urate transporter transcription unknown\",\n        \"Comprehensive interactome of ALDH16A1 not determined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TXN\",\n      \"SPG21\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"ALDH16A1 is a pseudoenzyme member of the aldehyde dehydrogenase superfamily that has lost catalytic aldehyde oxidation activity due to the absence of the conserved catalytic cysteine, as confirmed by crystal structure determination, SAXS, and in vitro enzymatic assays [PMID:30529746]. It retains the three-domain ALDH fold and forms a unique homodimer that mimics the classic ALDH dimer-of-dimers architecture [PMID:30529746]. ALDH16A1 is expressed in kidney proximal and distal tubule cells and zone 3 hepatocytes; knockout mice exhibit dysregulated urate transporter expression and altered lipid metabolism, indicating a non-enzymatic regulatory role in renal homeostasis [PMID:28254523]. ALDH16A1 directly binds thioredoxin (TXN), occluding its active site and promoting its lysosomal degradation, thereby sensitizing cells to ferroptosis within a SMARCA4–ALDH16A1–TXN regulatory axis [PMID:40897711].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying ALDH16A1's first physical interaction partner established that this uncharacterized ALDH family member participates in protein–protein interactions, specifically with the spastic paraplegia gene product maspardin/ACP33.\",\n      \"evidence\": \"Co-immunoprecipitation with mass spectrometry, reciprocal pull-down, and colocalization of overexpressed proteins in mammalian cells\",\n      \"pmids\": [\"19184135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequence of the ALDH16A1–maspardin interaction is unknown\",\n        \"Endogenous interaction not validated\",\n        \"No structural detail on the binding interface\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Computational analysis predicted that mammalian ALDH16A1 is a non-catalytic pseudoenzyme (lacking the essential Cys-302) and proposed an interaction with the purine salvage enzyme HPRT1 that could link ALDH16A1 to uric acid metabolism.\",\n      \"evidence\": \"Molecular modeling, sequence alignment across species, and structural prediction of HPRT1 binding\",\n      \"pmids\": [\"23348497\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"HPRT1 interaction was computationally predicted only and has not been experimentally validated\",\n        \"Pseudoenzyme status was inferred from sequence alone without biochemical confirmation\",\n        \"Gout-associated variant effect on interaction remains unconfirmed experimentally\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Generation of Aldh16a1 knockout mice revealed that loss of ALDH16A1 dysregulates urate transporters and lipid metabolism in the kidney, establishing an in vivo non-enzymatic regulatory function and defining its tissue expression pattern.\",\n      \"evidence\": \"Gene-targeted knockout mouse with RNA-seq, plasma metabolomics, and immunohistochemistry\",\n      \"pmids\": [\"28254523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular mechanism by which ALDH16A1 influences urate transporter expression is unknown\",\n        \"Direct binding partners mediating the renal phenotype were not identified\",\n        \"Single-lab study without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Crystal structures of bacterial ALDH16 and SAXS analysis of human ALDH16A1 definitively confirmed the pseudoenzyme status and revealed a unique three-domain fold with a C-terminal Rossmann-like domain that creates a novel dimeric architecture mimicking the classic ALDH tetramer.\",\n      \"evidence\": \"High-resolution X-ray crystallography of Loktanella ALDH16 (four structures), in vitro aldehyde oxidation and esterase assays, SAXS on recombinant human ALDH16A1\",\n      \"pmids\": [\"30529746\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No high-resolution crystal structure of human ALDH16A1 itself\",\n        \"Whether the NAD+-binding site in human ALDH16A1 retains any ligand-binding function is untested\",\n        \"Structural basis for any protein–protein interaction is unresolved\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that ALDH16A1 directly binds TXN, occludes its active site, and promotes its lysosomal degradation provided the first complete molecular mechanism for the pseudoenzyme, placing it in a SMARCA4–ALDH16A1–TXN axis that governs ferroptosis susceptibility in cancer cells.\",\n      \"evidence\": \"ATAC-seq, co-immunoprecipitation, TXN enzymatic activity assays, lysosomal translocation/degradation assays, SMARCA4 KO/rescue, and in vivo tumor models in NSCLC\",\n      \"pmids\": [\"40897711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of ALDH16A1–TXN binding and active-site occlusion has not been resolved at atomic resolution\",\n        \"Whether the SMARCA4–ALDH16A1–TXN axis operates in non-cancerous tissues (e.g., kidney) is unknown\",\n        \"Relationship between the TXN-regulatory function and the previously observed maspardin interaction is unexplored\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic-resolution structure of human ALDH16A1 in complex with TXN, whether the predicted HPRT1 interaction exists and connects to the renal urate phenotype, and how ALDH16A1's pseudoenzyme scaffold integrates maspardin binding with TXN regulation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of human ALDH16A1 alone or in complex with any partner\",\n        \"HPRT1 interaction never experimentally validated\",\n        \"Functional integration of maspardin and TXN interactions is completely unexplored\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TXN\",\n      \"SPG21\",\n      \"SMARCA4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}